This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.
Blijlevens N, Sonis S . Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817–26.
Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR . Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960–3967.
Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, Weinberg KI et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002; 100: 682–691.
Langner S, Staber PB, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275–280.
Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. A phase I/II randomized, placebo-control trial of Palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216–3222.
Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983–988.
Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383–388.
Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50: 53–58.
Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 2001; 50: 509–514.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van der Velden, W., Herbers, A. & Blijlevens, N. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant 43, 85–86 (2009). https://doi.org/10.1038/bmt.2008.269
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.269
This article is cited by
-
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2018)
-
The FGF family: biology, pathophysiology and therapy
Nature Reviews Drug Discovery (2009)